

Treatment-Naïve and Treatment-Experienced

# Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

Nelson DR, et al. Hepatology 2015;61:1127-35.

# Daclatasvir + Sofosbuvir for HCV GT 3

## ALLY-3 Trial: Study Features

### Daclatasvir + Sofosbuvir Trial: Features

- **Design:** Phase 3 open-label two-cohort study of daclatasvir (DCV) plus sofosbuvir (SOF) in treatment-naïve or experienced, chronic HCV GT 3
- **Setting:** Multiple centers in the United States
- **Entry Criteria**
  - Chronic HCV genotype 3
  - Treatment-naïve or treatment-experienced (prior NS5A experience excluded)
  - HCV RNA  $\geq 10,000$  IU/ml
  - Compensated cirrhosis allowed (METAVIR F4 on biopsy, FibroScan  $>14.6$  kPa or FibroTest/FibroSure score  $\geq 0.75$  with APRI  $>2$ )
- **Patient Groups**
  - N = 101 treatment-naïve GT3 patients received DCV + SOF x 12 weeks
  - N = 51 treatment-experienced GT3: DCV + SOF x 12 weeks
- **End-Points:** Primary = SVR12

# Daclatasvir + Sofosbuvir for HCV GT 3

## ALLY-3 Trial: Design

Week

0

12

24

Treatment-Naïve  
N = 101

**Daclatasvir + Sofosbuvir**

SVR12

Treatment-Experienced  
N = 51

**Daclatasvir + Sofosbuvir**

SVR12

### Drug Dosing

Daclatasvir: 60 mg once daily

Sofosbuvir: 400 mg once daily

# Daclatasvir + Sofosbuvir for HCV GT 3

## ALLY-3 Trial: Patient Characteristics

Characteristic	Treatment-Naïve (n=101)	Treatment-Experienced (n=51)
Male	58 (57%)	32 (63%)
Median age, years (range)	53 (24-67)	58 (40-73)
Race		
White	92 (91%)	45 (88%)
Black	4 (4%)	2 (4%)
Asian	5 (5%)	2 (4%)
HCV RNA $\geq$ 800,000 IU/ml	70 (69%)	38 (75%)
Cirrhosis	19 (19%)	13 (25%)
<i>IL28B</i> non-CC genotype	61 (60%)	31 (61%)
Prior treatment failure		
Relapse	N/A	31 (61%)
Partial response	N/A	2 (4%)
Null response	N/A	7 (14%)
Other <sup>a</sup>	N/A	11 (22%)


<sup>a</sup> Intolerant of therapy (n=6), virologic breakthrough (n=2), HCV never undetectable on tx (n=2)

Source: Nelson DR, et al. *Hepatology* 2015;61:1127-35.

# Daclatasvir + Sofosbuvir for HCV GT 3

## ALLY-3 Trial: Results


### ALLY-3: SVR12, by Baseline Characteristics Status



Note: SVR 12 based on HCV RNA less than lower limit of quantitation (25 IU/mL), detectable or undetectable

# Daclatasvir + Sofosbuvir for HCV GT 3 ALLY-3 Trial: Results

## ALLY-3: SVR12, by Cirrhosis Status



Note: 11 had missing or inconclusive findings for cirrhosis and not included in denominators

# Daclatasvir + Sofosbuvir for HCV GT 3

## ALLY-3 Trial: Adverse Events

Event	Daclatasvir + Sofosbuvir (n=152)
Serious Adverse Events (AEs)	1 (1%)
AEs leading to discontinuation	0
Grade 3 or 4 AEs	3 <sup>a</sup> (2%)
Adverse Events in ≥10% of patients	
Headache	30 (20%)
Fatigue	29 (19%)
Nausea	18 (12%)
Grade 3 or 4 Lab Abnormalities	
Hemoglobin < 9 g/dL	0
Neutrophils < 0.75 x 10 <sup>9</sup> /L	0
Platelets < 50 x 10 <sup>9</sup> /L	2 (1%)
Lipase > 3 x ULN	3 (2%)

<sup>a</sup>All were grade 3 AEs. ULN = upper limit of normal

# Daclatasvir + Sofosbuvir for HCV GT 3 ALLY-3 Trial: Conclusion

**Conclusion:** “A 12-week regimen of daclatasvir plus sofosbuvir achieved SVR12 in 96% of patients with genotype 3 infection without cirrhosis and was well tolerated. Additional evaluation to optimize efficacy in genotype 3-infected patients with cirrhosis is underway.”



This slide deck is from the University of Washington's *Hepatitis C Online* and *Hepatitis Web Study* projects.

Hepatitis C Online  
[www.hepatitisc.uw.edu](http://www.hepatitisc.uw.edu)

Hepatitis Web Study  
<http://depts.washington.edu/hepstudy/>

Funded by a grant from the Centers for Disease Control and Prevention.